XK
AERI

Xact Kapitalforvaltning’s Aerie Pharmaceuticals AERI Stock Holding History

Xact Kapitalforvaltning’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,551
Closed -$223K – 1451
2019
Q2 		$223K Hold
7,551
– – ﹤0.01% 1360
2019
Q1 		$359K Hold
7,551
– – 0.01% 1118
2018
Q4 		$273K Buy
7,551
+1,800
+31% +$84.4K 0.01% 1279
2018
Q3 		$354K Hold
5,751
– – 0.01% 1244
2018
Q2 		$388K Buy
5,751
+1,000
+21% +$56K 0.01% 1137
2018
Q1 		$258K Buy
+4,751
New +$266K 0.01% 1338

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Xact Kapitalforvaltning's AERI Position: Q3 2019 in Review

Xact Kapitalforvaltning sold out of Aerie Pharmaceuticals (AERI) in Q3 2019, closing a stake of 7,551 shares — an estimated $223K sold.

Xact Kapitalforvaltning first reported a position in AERI in Q1 2018 and held it in 6 quarters. The position peaked at $388K in Q2 2018. 167 funds tracked by Wall St. Rank hold AERI as of Q3 2019.

  • Xact Kapitalforvaltning reported no remaining Aerie Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 7,551 Aerie Pharmaceuticals shares in Q3 2019, an estimated $223K.
  • Xact Kapitalforvaltning first reported a position in Aerie Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • Xact Kapitalforvaltning's Aerie Pharmaceuticals position peaked at $388K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q3 2019, filed 31 Oct 2019.